+
Site Tour
CONGENITAL
HEART DEFECTS

SWITCH TO THE interventional VIEW    For more information specific to interventional cardiology regarding PDA closure

Patent Ductus Arteriosus Treatment

The American College of Cardiology noted that, in many cases, patent ductus arteriosus is now closed in infancy or childhood with catheter-based or surgical approaches.14

In clinical practice there are inconsistencies in therapy strategies, especially for small and hemodynamically insignificant PDA. Some clinicians support closure to eliminate the lifelong risk of infective endarteritis, and others maintain that it is unnecessary.4

 

When transcatheter patent ductus arteriosus closure is performed

When an infant is asymptomatic or well controlled on medical therapy, closure treatment may be delayed until transcatheter therapy can be offered.

Even when patients present with a small asymptomatic PDA, transcatheter device closure is a reasonable therapeutic approach.14


EARLY TRANSCATHETER INTERVENTION CAN IMPROVE OUTCOMES4

Early PDA closure can lead to rapid improvement in respiratory status and faster weaning off ventilator.
General PDA closure leads to proven benefits:

  • Faster weaning off mechanical ventilator
  • Oxygen supplementation
  • Improved weight gain
  • Faster decline in respiratory severity score (RSS)
  • Potential avoidance of pulmonary hypertension (PHT)

TRANSCATHETER CLOSURE

Transcatheter closure with the Amplatzer Piccolo™ Occluder can provide more definitive closure than medication and is less invasive than surgery.

  • Medication therapy has limited effectiveness (60–80%) and can have potential adverse effects in infants with PDA.14
  • Surgical ligation is more invasive than the occluder implanting procedure and may lead to significant procedural complications.11,14,15

ON DEMAND WEBINARS

Watch a series of recorded webinars that focus on preterms PDA closure from subject matter experts to stay up-to-date on the latest recommendations, clinical data and best practices.

Watch on demand PremiClose


STUDY DEMONSTRATING CASE FOR EARLY DEVICE INTERVENTION

LEARN MORE


INCREASED EXPERIENCE LEADS TO A MODIFIED PDA CLOSURE TECHNIQUE

LEARN MORE

Connext
Hub

Learn emerging and established information on cardiovascular conditions and stroke prevention technologies.

Find out more

References
  1. Sathanandam SK, Gutfinger D, O’Brien L et al. Amplatzer Piccolo Occluder clinical trial for percutaneous closure of the patent ductus arteriosus in patients ≥700 grams. Catheter Cardiovasc Interv. 2020;96(6):1266–1276. doi.org/10.1002/ccd.28973.
  2. Dice JE, Bhatia J. Patent ductus arteriosus: an overview. J Pediatr Pharmacol Ther. 2007;12(3):138–146. doi.org/10.5863/1551-6776-12.3.138.
  3. Kim LK. Patent ductus arteriosus (PDA). Medscape. emedicine.medscape.com/article/891096-overview. Accessed June 2023.
  4. Baruteau A-E, Hascoët S, Baruteau J et al. Transcatheter closure of patent ductus arteriosus: past, present and future. Arch Cardiovasc Dis. 2014;107(2):122–132. doi.org/10.1016/j.acvd.2014.01.008.
  5. Tripathi A, Black GB, Park Y-M M et al. Prevalence and management of patent ductus arteriosus in a pediatric Medicaid cohort. Clin Cardiol. 2013;36(9):502–506. doi.org/10.1002/clc.22150.
  6. Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation. 2006;114(17):1873-1882. doi.org/10.1161/CIRCULATIONAHA.105.592063
  7. Philip R, Waller BR III, Agrawal V et al. Morphologic characterization of the patent ductus arteriosus in the premature infant and the choice of transcatheter occlusion device. Catheter Cardiovasc Interv. 2016;87(2): 310–317. doi.org/10.1002/ccd.26287.
  8. Gillam-Krakauer M, Reese J. Diagnosis and management of patent ductus arteriosus. NeoReviews 2018;19(7):e394–e402. doi.org/10.1542/neo.19-7-e394.
  9. Chaudhary N, Filipov P, Bhutada A et al. Controversies in the management of patent ductus arteriosus in preterm infants. J Neonatal Biol. 2016;5(4):1000238. doi.org/10.4172/2167-0897.1000238. www.walshmedicalmedia.com/open-access/controversies-in-the-management-of-patent-ductus-arteriosusin- preterminfants-2167-0897-1000238.pdf. Accessed June 2023.
  10. Nady ME, Amrousy DE, Salah N et al. Transcatheter versus surgical closure of patent ductus ateriosus in pediatric patients: A systematic review with meta-analysis. SM J Pediatr Surg. 2017;3(4):1054. www.jsmcentral.org/sm-pediatric-surgery/fulltext_smjps-v3-1054.pdf. Accessed June 2023.
  11. Zahn EM, Peck D, Phillips A et al. Transcatheter closure of patent ductus arteriosus in extremely premature newborns: Early results and midterm follow-up. JACC Cardiovasc Interv. 2016;9(23):2429–2437. doi.org/10.1016/j.jcin.2016.09.019.
  12. Van Overmeire B, Smets K, Lecoutere D et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000;343(10):674–681. doi.org/10.1056/NEJM200009073431001.
  13. Stout KK, Daniels CJ, Aboulhosn JA et al. 2018 AHA/ACC Guideline for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(14):e698–e800. doi.org/10.1161/ CIR.0000000000000603.
  14. Warnes CA, Williams RG, Bashore TM et al. ACC/AHA 2008 Guidelines for the management of adults with congenital heart disease. J Am Coll Cardiol. 2008;52(23):e143– e263. doi.org/10.1016/j.jacc.2008.10.001.
  15. Ashrafi AH, Levy VY. Management strategies for the preemie ductus. Curr Opin Cardiol. 2019;34(1):41–45. doi.org/10.1097/HCO.0000000000000580.
  16. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics. 2010;125(5):1020–1030. doi.org/10.1542/peds.2009-3506.
  17. Amplatzer Piccolo Occluder Instructions for Use.

© Abbott 2024. All rights reserved. 9-EH-5-14533-01 05-2024 REV A

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline